Target family: Tachykinin receptors (type: gpcr)
Target: NK<sub>1</sub> receptor

Ligand: vestipitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.369999885559082 pKi
Reference (Journal): Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Published in: J Med Chem

Ligand: aprepitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2003)
Primary target: yes
Median affinity: 10.050000190734863 pKi
Reference (Journal): Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Published in: J Med Chem

Ligand: aprepitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2003)
Primary target: yes
Median affinity: 10.050000190734863 pKi
Reference (Journal): Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Published in: J Med Chem

Ligand: befetupitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: casopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.
Published in: J Recept Signal Transduct Res

Ligand: casopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Neurokinin-1 receptor antagonists: a comprehensive patent survey.
Published in: Expert Opin Ther Pat

Ligand: CP 99994 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Published in: Eur J Pharmacol

Ligand: CP 99994 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: eledoisin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.6 pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: ezlopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.7 pKi
Reference (Journal): Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Published in: Pharmacology

Ligand: FK 224 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity.
Published in: J Pharmacol Exp Ther

Ligand: FK-888 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.1 pKi
Reference (Journal): A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients.
Published in: Am J Respir Crit Care Med

Ligand: fosaprepitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2008)
Primary target: no
Median affinity: 8.920000076293945 pIC50
Reference (Journal): Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Published in: J Med Chem

Ligand: hemokinin 1 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Published in: Br J Pharmacol

Ligand: imnopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.239999771118164 pKi
Reference (Journal): Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: kassinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: L-703,606 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: L-732,138 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.640000343322754 pIC50
Reference (Journal): Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor.
Published in: J Biol Chem

Ligand: L-732,138 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pIC50
Reference (Journal): Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor.
Published in: J Biol Chem

Ligand: L760735 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.720000267028809 pIC50
Reference (Journal): An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
Published in: J Med Chem

Ligand: lanepitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.819999694824219 pIC50
Reference (Journal): Neurokinin-1 receptor antagonists: a comprehensive patent survey.
Published in: Expert Opin Ther Pat

Ligand: lanepitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: netupitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Median affinity: 9.02 pKi
Reference (Journal): Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: neurokinin A (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells.
Published in: FEBS Lett

Ligand: neurokinin A (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: neurokinin A (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.
Published in: FEBS Lett

Ligand: neurokinin A (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Published in: Br J Pharmacol

Ligand: neurokinin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: neuropeptide-γ (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: neuropeptide K (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: nolpitantium (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: osanetant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.6 pIC50
Reference (Journal): Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801.
Published in: Eur J Pharmacol

Ligand: osanetant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Published in: Eur J Pharmacol

Ligand: phyllomedusin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: physalaemin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: [Pro9]SP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): Substance P(6-11) and natural tachykinins interact with septide-sensitive tachykinin receptors coupled to a phospholipase C in the rat urinary bladder.
Published in: Neuropeptides

Ligand: R116031 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.35 pKi
Reference (Journal): Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: R-486 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Published in: Eur J Pharmacol

Ligand: rolapitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2015), EMA (2017)
Median affinity: 9.18 pKi
Reference (Journal): Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Published in: Pharmacol Biochem Behav

Ligand: RP67580 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580.
Published in: J Biol Chem

Ligand: saredutant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: saredutant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Published in: Eur J Pharmacol

Ligand: [Sar9,Met(O2)11]SP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: SCH 206272 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Published in: Eur J Pharmacol

Ligand: septide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Published in: Br J Pharmacol

Ligand: septide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.
Published in: FEBS Lett

Ligand: serlopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.220000267028809 pIC50
Reference (Journal): Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Published in: J Med Chem

Ligand: spantide I (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.6 pEC50
Reference (Journal): Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect.
Published in: Regul Pept

Ligand: spantide I (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): The antagonism of bombesin in the CNS by substance P analogues.
Published in: Life Sci

Ligand: spantide I (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pA2
Reference (Journal): Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect.
Published in: Regul Pept

Ligand: spantide I (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.279999732971191 pIC50
Reference (Journal): Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity.
Published in: Proc Natl Acad Sci USA

Ligand: spantide I (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pA2
Reference (Journal): Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity.
Published in: Proc Natl Acad Sci USA

Ligand: spantide II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity.
Published in: Proc Natl Acad Sci USA

Ligand: spantide II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pA2
Reference (Journal): Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity.
Published in: Proc Natl Acad Sci USA

Ligand: spantide II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.5 pEC50
Reference (Journal): Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect.
Published in: Regul Pept

Ligand: spantide II (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pA2
Reference (Journal): Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect.
Published in: Regul Pept

Ligand: substance P (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Published in: Br J Pharmacol

Ligand: substance P (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.
Published in: Bioorg Med Chem

Ligand: substance P-(4-11) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: substance P-(6-11) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: substance P-OMe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Published in: J Biol Chem

Ligand: [125I]BH-[Sar9,Met(O2)11]SP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9 pKd
Reference (Journal): 125I-BH[Sar9, Met(O2)11]-SP, a new selective ligand for the NK-1 receptor in the central nervous system.
Published in: Brain Res

Ligand: [125I]L703,606 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKd
Reference (Journal): Radioiodinated L-703,606: a potent, selective antagonist to the human NK1 receptor.
Published in: Appl Radiat Isot

Ligand: [125I]SP (human, mouse, rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [18F]SPA-RQ (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET.
Published in: J Label Comp Radiopharm

Ligand: [3H]BH-[Sar9,Met(O2)11]SP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKd
Reference (Journal): Binding sites for [3H][Sar9, Met(O2)11]substance P in rat brain and guinea pig ileum.
Published in: Brain Res

Ligand: [3H]SP (human, mouse, rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pKd
Reference (Journal): Specific binding of [3H]substance P to the rat submaxillary gland. The effects of ions and guanine nucleotides.
Published in: J Pharmacol Exp Ther

Ligand: T2328 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 10.1 pKi
Reference (Journal): Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Published in: J Pharmacol Sci

Ligand: TAK-637 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.350000381469727 pIC50
Reference (Journal): Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.
Published in: J Med Chem

Ligand: tradipitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pKi
Reference (Patent): Triazole derivatives as tachykinin receptor antagonists

Ligand: vestipitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.369999885559082 pKi
Reference (Journal): Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
Published in: Eur Neuropsychopharmacol

Ligand: vofopitant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 10.6 pKi
Reference (Journal): GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.
Published in: Regul Pept

Ligand: ZD6021 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.9 pIC50
Reference (Journal): Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Published in: J Pharmacol Exp Ther